Investment Thesis
With its low up-front costs, Omnipod of Insulet Corporation (PODD) has positioned itself to become diabetics’ first choice in pump therapy as they wean off the daily injections. The company’s top line has expanded at a compound annual growth rate ((CAGR)) of 29% in the last three years, and Insulet now targets $1 billion in revenue by 2021 at 21% of CAGR.
The innovative pipeline, better third-party reimbursements, and the focus on pharmacy channel could expand the domestic market share while the start of direct European operations could lift the international